Kenakin Terry
Department of Biological Reagents and Assay Development, GlaxoSmithKline Research, and Development, Research Triangle Park, NC 27709, USA.
Comb Chem High Throughput Screen. 2008 Jun;11(5):337-43. doi: 10.2174/138620708784534824.
In high throughput screening systems, a single concentration of a new compound is tested in a biological system to detect direct effects (agonists) or effects on other ligands (antagonists). In this latter case, the chemical context of the assay is defined by a balance of maximal sensitivity (limited agonist concentration) and maximal window to observe effect (sizable agonist concentration to induce measurable effect). For allosteric modulators, there are other factors that should be considered in high throughput screening environments. Specifically, the saturable aspect of allosteric effect can dissociate the observed ordinate change in response (% inhibition) and potency of effect (concentration at which a given ordinate % effect is obtained). Also, the specter of probe dependence can be important in systems where the physiologically relevant agonist cannot be used for screening (i.e. HIV-1 entry). Finally, the interactive nature of allosteric systems can cause complex relationships between the chemical context of an assay and potency of allosteric modulator. For example, in cases where the efficacy of an agonist is reduced but the affinity is increased by a modulator, it may be more beneficial to have higher concentrations of agonist in the screening assay to optimize sensitivity to modulators. This must be balanced for allosteric potentiators with the need to retain a window to observe increased agonist effect.
在高通量筛选系统中,会在生物系统中测试单一浓度的新化合物,以检测其直接效应(激动剂)或对其他配体的效应(拮抗剂)。在后一种情况下,检测的化学环境由最大灵敏度(有限的激动剂浓度)和观察效应的最大窗口(足以诱导可测量效应的可观激动剂浓度)之间的平衡来定义。对于变构调节剂而言,在高通量筛选环境中还应考虑其他因素。具体来说,变构效应的可饱和性可能会使观察到的纵坐标变化响应(%抑制率)与效应强度(获得给定纵坐标%效应时的浓度)相分离。此外,在无法使用生理相关激动剂进行筛选的系统(如HIV-1进入)中,探针依赖性问题可能很重要。最后,变构系统的相互作用性质可能会导致检测的化学环境与变构调节剂强度之间产生复杂的关系。例如,在激动剂的效力降低但亲和力因调节剂而增加的情况下,在筛选检测中使用较高浓度的激动剂可能更有利于优化对调节剂的灵敏度。对于变构增强剂而言,这必须与保留观察激动剂效应增强窗口的需求相平衡。